Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer | Access and Reimbursement | Realizing the Potential of Personalized Medicine in Oncology | US | 2016

Biomarker-driven prescribing plays an increasingly prominent role in key oncology indications. The choice of therapy for breast cancer has long been informed by the presence of key biomarkers, and EGFR and ALK status are well-established markers for determining treatment in non-small-cell lung cancer (NSCLC). Treatment of ovarian cancer has only recently begun to benefit from this trend, but the role of biomarkers will continue to evolve in all three indications.

Login to access report